EcoDrugPlus

Peroxisome Proliferator-Activated Receptor Alpha-Like

Ensembl ID : ENSBSLG00000026071
Gene Symbol: LOC114857104
3 Cross references
397 Possible Orthologues:

Phosphatidylinositol 3-Kinase Regulatory Subunit Alpha-Like

Ensembl ID : ENSBSLG00000018426
Gene Symbol: LOC114861410
2 Cross references
197 Possible Orthologues:

Phosphatidylinositol 3-Kinase Regulatory Subunit Gamma-Like

Ensembl ID : ENSBSLG00000011331
Gene Symbol: LOC114854785
2 Cross references
191 Possible Orthologues:

Phosphatidylinositol 3-Kinase Regulatory Subunit Gamma-Like

Ensembl ID : ENSBSLG00000026300
Gene Symbol: LOC114845055
3 Cross references
190 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha

Ensembl ID : ENSBSLG00000002314
Gene Symbol: PIK3CA
3 Cross references
202 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha

Ensembl ID : ENSBSLG00000024054
Gene Symbol: PIK3CA
3 Cross references
194 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Beta

Ensembl ID : ENSBSLG00000013020
Gene Symbol: PIK3CB
3 Cross references
217 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Delta

Ensembl ID : ENSBSLG00000008781
Gene Symbol: PIK3CD
3 Cross references
214 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma

Ensembl ID : ENSBSLG00000020102
Gene Symbol: PIK3CG
3 Cross references
216 Possible Orthologues:

Phosphodiesterase 10a

Ensembl ID : ENSBSLG00000018509
Gene Symbol: PDE10A
3 Cross references
207 Possible Orthologues:

Phosphodiesterase 3a

Ensembl ID : ENSBSLG00000010316
Gene Symbol: PDE3A
3 Cross references
203 Possible Orthologues:

Phosphodiesterase 3a

Ensembl ID : ENSBSLG00000008396
Gene Symbol: PDE3A
3 Cross references
186 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).